Compare · NEOV vs TMO
NEOV vs TMO
Side-by-side comparison of NeoVolta Inc. (NEOV) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- NEOV operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 2074.2x NEOV ($84.1M).
- Over the past year, NEOV is down 32.2% and TMO is up 14.9% - TMO leads by 47.1 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 11 for NEOV).
- TMO has more recent analyst coverage (25 ratings vs 2 for NEOV).
- Company
- NeoVolta Inc.
- Thermo Fisher Scientific Inc
- Price
- $1.98+1.54%
- $469.56-0.67%
- Market cap
- $84.1M
- $174.52B
- 1M return
- -19.84%
- -1.03%
- 1Y return
- -32.19%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 17
- Recent ratings
- 2
- 25
NeoVolta Inc.
NeoVolta Inc. designs, manufactures, and sells energy storage systems in the United States. It offers NV14 and NV 24 energy storage systems to store and use energy through batteries and an inverter at residential or commercial sites. The company markets and sells its products directly to certified solar installers and solar equipment distributors. NeoVolta Inc. was founded in 2018 and is headquartered in Poway, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest NEOV
- Executive Vice President Bond Steve bought $85,626 worth of shares (43,000 units at $1.99), increasing direct ownership by 5% to 840,000 units (SEC Form 4)
- NeoVolta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by NeoVolta Inc.
- Infinite Grid Capital Signs 1.1 GWh BESS Supply LOI with NeoVolta to Power U.S. AI Infrastructure Buildout
- NeoVolta Announces Pricing of Public Offering of Common Stock
- NeoVolta Signs First BESS Supply LOI with Infinite Grid Capital for Approximately $200 Million in Utility-Scale Deployments
- SEC Form 424B5 filed by NeoVolta Inc.
- NeoVolta Announces Proposed Public Offering of Common Stock
- Executive Vice President Bond Steve bought $98,131 worth of shares (47,000 units at $2.09), increasing direct ownership by 6% to 797,000 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Nealis Jing
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)